TechniScan, Inc. (TSNI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
TechniScan, Inc. (TSNI) trades at $0.00 with AI Score 46/100 (Grade C). TechniScan, Inc. is a development-stage company focused on creating non-invasive medical imaging products for breast cancer detection. Market cap: $1,458, Sector: Industrials.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for TSNI: TSNI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TSNI against Industrials peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
TSNI: the 1 perspectives are evenly split.
How is this calculated? →TechniScan, Inc. (TSNI) Industrial Operations Profile
TechniScan, Inc. is a development-stage medical technology company based in Salt Lake City, Utah, specializing in non-invasive breast cancer detection. It is focused on commercializing the Warm Bath Ultrasound system, an innovative imaging device intended to provide detailed tissue analysis for radiologists.
What Is the Investment Thesis for TSNI?
TechniScan, Inc. presents an investment profile centered on its development-stage status and the potential of its Warm Bath Ultrasound system for non-invasive breast cancer detection. The company's strategic value proposition lies in addressing the growing demand for advanced diagnostic tools that offer both efficacy and patient comfort. With a market capitalization of 1K and a small operational team of five employees, TSNI is in the early phases of commercialization, focusing on research and development. The reported Beta of -12.35, while highly unusual and indicative of extremely low liquidity and trading volume, underscores the speculative nature inherent in development-stage OTC companies. Key growth catalysts would include successful completion of clinical trials, securing necessary regulatory approvals (e.g., FDA clearance), and subsequent market penetration of its Warm Bath Ultrasound system. Value drivers are intrinsically linked to the perceived efficacy and market adoption of its proprietary technology. However, significant risks persist, including the challenges of securing adequate funding for continued development, the highly competitive medical imaging market, and the inherent uncertainties of regulatory pathways. Investors must recognize the substantial execution risk and the long lead times typically associated with medical device commercialization.
Based on FMP financials and quantitative analysis
TSNI Key Highlights
- TechniScan, Inc. operates as a development-stage company, concentrating its resources on the research and commercialization of non-invasive medical imaging products.
- The company's primary product in development is the Warm Bath Ultrasound system, designed for advanced detection and diagnosis of breast cancer.
- TSNI maintains a very small operational footprint with just 5 employees, characteristic of an early-stage enterprise focused on core R&D activities.
- The company's market capitalization is reported as $0.00B, reflecting its pre-revenue or minimal valuation status typical for development-stage entities.
- A reported Beta of -12.35 indicates highly unusual trading behavior, likely due to extremely limited liquidity and trading activity on the OTC market.
Who Are TSNI's Competitors?
TSNI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| EKIVF Enka Insaat ve Sanayi A.S. | $1.12 | +7.14% | $6.39B | 64 |
| AGX Argan, Inc. | $738.72 | +4.61% | $10.36B | 62 |
| LGN Legence Corp. | $77.08 | +1.64% | $9.33B | 60 |
| ECG Everus Construction Group, Inc. | $143.13 | +3.52% | $7.31B | 59 |
| KBAGF Koninklijke BAM Groep nv | $12.80 | +22.84% | $3.29B | 49 |
| MSW Ming Shing Group Holdings Limited | $1.30 | +2.36% | $16.87M | 49 |
| APG APi Group Corporation | $42.70 | +1.70% | $18.50B | 49 |
| BOUYF Bouygues S.A. | $59.34 | +0.00% | $22.91B | 49 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TSNI's Key Strengths?
- Focus on non-invasive breast cancer detection, aligning with market demand for patient-friendly diagnostics.
- Development of a proprietary Warm Bath Ultrasound system, potentially offering unique diagnostic insights.
- Addresses a critical and large medical need in oncology diagnostics.
- Lean operational structure with a small, focused team of 5 employees.
What Are TSNI's Weaknesses?
- Operates as a development-stage company with no reported commercialized products or revenue.
- Trades on the OTC Other market, implying limited liquidity and disclosure requirements.
- Market capitalization of 1K indicates minimal valuation and significant funding challenges.
- Highly unusual and negative Beta of -12.35 suggests extreme volatility and/or lack of meaningful trading activity.
What Could Drive TSNI Stock Higher?
- Successful completion of preclinical or early-stage clinical trials for the Warm Bath Ultrasound system, demonstrating safety and preliminary efficacy.
- Securing additional funding rounds or strategic investments to support ongoing research, development, and regulatory processes.
- Achievement of key regulatory milestones, such as submitting applications for market clearance (e.g., FDA 510(k) or PMA) for its imaging device.
- Continued progress in the research and development of the Warm Bath Ultrasound system, moving closer to a market-ready product.
What Are the Key Risks for TSNI?
- Significant funding risk, as a development-stage company with a 1K market cap, it requires substantial capital for R&D and commercialization.
- High regulatory risk, as medical devices require extensive testing and approvals from health authorities before market entry.
- Commercialization risk, as there is no guarantee that the Warm Bath Ultrasound system will achieve market acceptance or compete effectively against established technologies.
- Operational risk due to a small team of 5 employees, which may limit the company's capacity to manage complex development and commercialization efforts.
- Intense competition within the medical imaging and breast cancer diagnostics market from larger, well-funded companies with existing products.
What Are the Growth Opportunities for TSNI?
- Growth opportunity 1: Successful commercialization of the Warm Bath Ultrasound system represents the primary growth driver for TechniScan, Inc. The global market for breast cancer diagnostics is significant, with a continuous demand for improved detection methods. If the Warm Bath Ultrasound system can demonstrate superior diagnostic accuracy or patient comfort compared to existing technologies, it could capture a meaningful share of this market. The timeline for this opportunity is contingent on clinical trial success, regulatory approvals, and effective market entry strategies, likely spanning several years post-development.
- Growth opportunity 2: Expansion into broader diagnostic applications beyond breast cancer could unlock substantial market potential. While currently focused on breast cancer, the underlying ultrasound technology of the Warm Bath system might be adaptable for imaging other soft tissues or organs. This diversification would broaden the company's addressable market and reduce reliance on a single product application. Such expansion would require additional research and development, clinical validation, and regulatory processes, suggesting a longer-term growth trajectory.
- Growth opportunity 3: Strategic partnerships and licensing agreements with larger medical device manufacturers or distributors could accelerate market penetration. As a small, development-stage company, TechniScan, Inc. could benefit significantly from the established sales channels, marketing expertise, and financial resources of a larger partner. Such collaborations could expedite the commercial launch of the Warm Bath Ultrasound system and facilitate its adoption in hospitals and diagnostic centers globally, potentially shortening the time to revenue generation.
- Growth opportunity 4: Leveraging the trend towards non-invasive and patient-friendly diagnostic procedures offers a significant avenue for growth. Patients increasingly seek diagnostic options that minimize discomfort and radiation exposure. The Warm Bath Ultrasound system, being non-invasive and ultrasound-based, aligns perfectly with this market preference. Promoting these benefits could differentiate the product in a crowded market and appeal to a broader patient demographic, driving adoption rates once the product is commercially available.
- Growth opportunity 5: Continuous technological innovation and product enhancements could sustain long-term growth. Future iterations of the Warm Bath Ultrasound system could incorporate advanced features, such as AI-powered image analysis, enhanced resolution, or integration with other diagnostic modalities. These improvements would ensure the product remains competitive and relevant in a rapidly evolving medical technology landscape, attracting new customers and retaining existing ones. This ongoing development would be crucial for maintaining a technological edge and expanding market share over time.
What Opportunities Does TSNI Have?
- Growing global demand for early and accurate breast cancer detection technologies.
- Increasing preference for non-invasive diagnostic procedures among patients and healthcare providers.
- Potential for strategic partnerships or licensing agreements to accelerate commercialization and market reach.
- Future technological advancements could enhance the capabilities and applications of its ultrasound system.
What Threats Does TSNI Face?
- Intense competition from established medical imaging companies with existing breast cancer diagnostic solutions.
- Significant capital requirements for ongoing research, development, clinical trials, and regulatory approvals.
- Risks associated with regulatory hurdles and the lengthy process of obtaining market clearance for medical devices.
- Challenges inherent in commercializing a new medical technology and achieving market adoption.
What Are TSNI's Competitive Advantages?
- Proprietary technology in the form of the Warm Bath Ultrasound system, offering a unique approach to breast tissue characterization.
- Focus on non-invasive diagnostic methods, aligning with patient preferences and potentially reducing procedural discomfort.
- Specialized application in breast cancer detection, addressing a significant and persistent medical need.
- Potential for intellectual property protection (patents) surrounding its unique ultrasound imaging methodology.
What Does TSNI Do?
TechniScan, Inc. is a development-stage enterprise dedicated to the research, development, and eventual commercialization of advanced non-invasive medical imaging products. Headquartered in Salt Lake City, Utah, the company's core mission revolves around enhancing the early detection and diagnosis of breast cancer, a critical area within global healthcare. The cornerstone of TechniScan's product pipeline is the Warm Bath Ultrasound system. This innovative device is an ultrasound-based imaging technology engineered to offer radiologists comprehensive information regarding the bulk properties of breast tissue, alongside high-resolution images of the tissue structure itself. The company's strategic focus is on developing a diagnostic tool that can provide more detailed and potentially earlier insights into breast abnormalities compared to conventional methods, all while maintaining a non-invasive approach. As a development-stage entity, TechniScan, Inc. is primarily engaged in the foundational phases of product creation, including extensive research, technological refinement, and the necessary steps toward regulatory approval and market introduction. The company operates with a lean team of five employees, reflecting its early-stage status and concentrated efforts on core development activities. Its positioning within the medical technology sector underscores a commitment to leveraging technological advancements to address significant unmet medical needs, particularly in oncology diagnostics. The potential impact of a successful Warm Bath Ultrasound system could be substantial, offering a novel diagnostic pathway for healthcare providers and patients alike, by aiming to improve diagnostic accuracy and patient comfort.
What Products and Services Does TSNI Offer?
- Researches and develops non-invasive medical imaging products.
- Focuses on technologies for the detection and diagnosis of breast cancer.
- Intends to commercialize the Warm Bath Ultrasound system.
- Develops an ultrasound-based imaging device.
- Aims to provide radiologists with information about breast tissue bulk properties.
- Generates images of breast tissue structure.
- Operates as a development-stage company.
How Does TSNI Make Money?
- Currently, the business model is primarily focused on research and development activities to advance its proprietary Warm Bath Ultrasound system.
- Future revenue generation is anticipated from the sale of its non-invasive medical imaging products, specifically the Warm Bath Ultrasound system, to healthcare providers.
- Potential for licensing its technology or intellectual property to larger medical device companies for broader market reach and distribution.
- May generate revenue through service agreements for maintenance and support of its imaging systems once commercialized.
What Industry Does TSNI Operate In?
TechniScan, Inc. operates within the broader medical technology sector, specifically targeting the diagnostic imaging segment with a focus on breast cancer detection. This industry is characterized by continuous innovation, driven by the imperative for earlier and more accurate disease diagnosis, alongside a growing preference for less invasive procedures. The global market for breast imaging is substantial, propelled by rising cancer incidence rates and increasing awareness regarding early detection. Key trends include the integration of artificial intelligence, advancements in imaging resolution, and the development of patient-friendly diagnostic modalities. TechniScan's Warm Bath Ultrasound system positions the company within the competitive landscape of breast imaging technologies, which includes mammography, MRI, and traditional ultrasound. Its non-invasive, ultrasound-based approach aims to carve out a niche by offering distinct advantages in tissue characterization, potentially complementing or improving upon existing diagnostic pathways.
Who Are TSNI's Key Customers?
- Radiologists and diagnostic imaging specialists seeking advanced breast cancer detection tools.
- Hospitals and medical centers looking to upgrade or expand their diagnostic imaging capabilities.
- Specialized breast health clinics and oncology centers.
- Potentially, research institutions interested in advanced ultrasound imaging technology.
How TechniScan, Inc. Is Valued
Relative to its peer group, TSNI's quantitative score of 46/100 is below the peer average of 59/100.
TSNI Financials
Bull Case vs Bear Case
Bull Case
- Focus on non-invasive breast cancer detection, aligning with market demand for patient-friendly diagnostics.
- Development of a proprietary Warm Bath Ultrasound system, potentially offering unique diagnostic insights.
- Addresses a critical and large medical need in oncology diagnostics.
- Lean operational structure with a small, focused team of 5 employees.
Bear Case
- Operates as a development-stage company with no reported commercialized products or revenue.
- Trades on the OTC Other market, implying limited liquidity and disclosure requirements.
- Market capitalization of 1K indicates minimal valuation and significant funding challenges.
- Highly unusual and negative Beta of -12.35 suggests extreme volatility and/or lack of meaningful trading activity.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
TSNI Latest News
No recent news available for TSNI.
TSNI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TSNI.
Price Targets
Wall Street price target analysis for TSNI.
TSNI MoonshotScore
What does this score mean?
The MoonshotScore rates TSNI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: David C. Robinson
Chief Executive Officer
The provided information indicates David C. Robinson is responsible for managing TechniScan, Inc.'s team of 5 employees. Specific details regarding his educational background, prior career history, or previous roles within the medical technology or engineering sectors are not available in the provided source data. His role as the manager of the company's small team suggests a hands-on leadership position in guiding the development-stage company's strategic direction and operational execution.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to David C. Robinson's leadership are not detailed in the provided source data. As the manager of a development-stage company with 5 employees, his track record would likely involve overseeing the research and development efforts for the Warm Bath Ultrasound system and navigating the initial phases of commercialization.
TSNI OTC Market Information
TechniScan, Inc. trades on the 'OTC Other' tier of the OTC market. This tier typically includes companies that do not meet the minimum financial or disclosure standards of higher OTC tiers like OTCQX or OTCQB, nor do they qualify for listing on major exchanges such as the NYSE or NASDAQ. Companies in the 'OTC Other' category often have limited public information, may not regularly file financial reports with the SEC, and can be considered highly speculative. This contrasts sharply with NYSE or NASDAQ-listed companies, which must adhere to stringent listing requirements regarding market capitalization, share price, corporate governance, and regular, comprehensive financial reporting.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public information and disclosure, making it difficult for investors to conduct thorough due diligence.
- Extremely low trading volume and liquidity, leading to wide bid-ask spreads and difficulty in executing trades.
- Increased susceptibility to price manipulation due to low float and minimal regulatory oversight compared to major exchanges.
- Lack of institutional investor interest and analyst coverage, further limiting market transparency and price discovery.
- Potential for delisting or further restrictions if the company fails to meet even minimal reporting requirements.
- Verify any available financial statements or disclosures, however infrequent or limited.
- Research the company's management team for credibility and relevant experience, beyond what is publicly stated.
- Assess the viability and market potential of the Warm Bath Ultrasound system, including any clinical data or regulatory progress.
- Investigate any legal or regulatory actions against the company or its management.
- Understand the company's funding status and future capital requirements for development and commercialization.
- Evaluate the competitive landscape within breast cancer diagnostics and TechniScan's potential differentiation.
- Consider the potential for dilution from future capital raises, which is common for development-stage companies.
- The company is officially incorporated in Salt Lake City, Utah, indicating a legal entity.
- It has a stated focus on a specific medical technology product (Warm Bath Ultrasound system).
- The company has a known CEO, David C. Robinson, managing its 5 employees.
- Its business description outlines a clear intent for research, development, and commercialization.
TSNI Industrials Stock FAQ
What does TechniScan, Inc. do?
TechniScan, Inc. is a development-stage company primarily engaged in the research, development, and future commercialization of non-invasive medical imaging products. Its core focus is on improving the detection and diagnosis of breast cancer through advanced technology. The company is developing the Warm Bath Ultrasound system, an innovative ultrasound-based device designed to provide radiologists with detailed information about the bulk properties and structural images of breast tissue. This technology aims to offer a non-invasive diagnostic alternative or complement to existing methods, headquartered in Salt Lake City, Utah, with a small team dedicated to bringing this system to market.
What are the key challenges for a development-stage company like TechniScan, Inc. in the medical imaging sector?
As a development-stage company in the medical imaging sector, TechniScan, Inc. faces several significant challenges. Foremost among these is securing adequate and consistent funding to support extensive research, development, and clinical trials required for medical device commercialization. The regulatory pathway for medical imaging devices is rigorous, demanding substantial time and resources for approvals like FDA clearance. Furthermore, the medical imaging market is highly competitive, dominated by established players with significant R&D budgets and distribution networks. TechniScan must also navigate the inherent risks of product development, including potential technical hurdles, delays in trials, and the ultimate challenge of achieving market adoption against entrenched technologies.
How does TechniScan, Inc.'s OTC Other listing impact investors?
TechniScan, Inc.'s listing on the 'OTC Other' tier of the OTC market has several critical implications for investors. This tier is characterized by minimal disclosure requirements, meaning investors may have access to very limited financial and operational information, making informed decisions challenging. Liquidity is typically extremely low, as evidenced by the company's 1K market cap and highly negative Beta, leading to wide bid-ask spreads and difficulty in buying or selling shares efficiently. Such an environment also increases the risk of price volatility and potential manipulation due to thin trading. Investors should be aware that 'OTC Other' stocks carry a higher degree of speculative risk compared to those listed on major exchanges with stricter oversight.
What are the key factors to evaluate for TSNI?
TechniScan, Inc. (TSNI) holds an AI score of 46/100 (low). Not financial advice.
How frequently does TSNI data refresh on this page?
TSNI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven TSNI's recent stock price performance?
TechniScan, Inc. (TSNI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on non-invasive breast cancer detection, aligning with market demand for patient-friendly diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TSNI overvalued or undervalued right now?
Valuing TechniScan, Inc. (TSNI) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying TSNI?
Before investing in TechniScan, Inc. (TSNI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's development-stage status and OTC Other listing.
- Specific financial performance metrics (e.g., revenue, profit) are not available in the provided data, consistent with a 1K market cap.
- The Beta value of -12.35 is highly unusual and likely a statistical artifact of extremely low trading volume and liquidity, rather than a true reflection of market correlation.